TD Cowen Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX)
Analysts at TD Cowen started coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating on the stock. CRNX has been the subject of a number of other reports. Wolfe Research started coverage on shares of Crinetics Pharmaceuticals in […]
![TD Cowen Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX)](https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/crinetics-pharmaceuticals-inc-logo-1200x675.png&w=240&h=240&zc=2)